InvestorsObserver
×
News Home

What is Wall Street's Target Price for Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Wednesday?

Wednesday, May 11, 2022 09:54 AM | InvestorsObserver Analysts

Mentioned in this article

What is Wall Street's Target Price for Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Wednesday?

Wall Street is positive on Corbus Pharmaceuticals Holdings Inc (CRBP). On average, analysts give Corbus Pharmaceuticals Holdings Inc a Buy rating. The average price target is $1.98, which means analysts expect the stock to climb by 607.14% over the next twelve months. That average ranking earns Corbus Pharmaceuticals Holdings Inc an Analyst Rating of 21, which is better than 21% of stocks based on data compiled by InvestorsObserver.

Overall Score - 3.7
Wall Street analysts are rating CRBP a Buy today. Find out what this means to you and get the rest of the rankings on CRBP!

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Corbus Pharmaceuticals Holdings Inc Stock Today?

Corbus Pharmaceuticals Holdings Inc (CRBP) stock is trading at $0.28 as of 9:50 AM on Wednesday, May 11, a rise of $0.02, or 8.53% from the previous closing price of $0.26. The stock has traded between $0.26 and $0.28 so far today. Volume today is less active than usual. So far 30,112 shares have traded compared to average volume of 663,825 shares. Click Here to get the full Stock Report for Corbus Pharmaceuticals Holdings Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App